Study in Norway reveals that the majority of the women w/ SpA were not treated with TNF inhibitors before or during pregnancy. Few on TNFi were continued on tx during pregnancy. #EULAR2020 @RheumNow https://t.co/t7B6pASeWQhttps://t.co/BwU6RF5Qkn
Switching TNFi to VDZ in pts IBD-related SpA associated w/ articular exacerbation of SpA in 1 out of 4 patients within the first 5 months. New-onset MEM is also observed in up to 15% of patients with IBD treated with VDZ. #EULAR2020 @RheumNow https://t.co/ZVjZC7hvxshttps://t.co/d1RT3GzB2b
#EULAR2020 #op0225 sub study of OPAL Balance: withdrawal of MTxdoes not negatively impact Tofa efficacy in PsA. At 6 mo deltaPASDAS 0.229 (0.079) for tofa mono & 0.q138 (0.081) for tofa+mtx. LFT elevation more common in combination arm @RheumNow https://t.co/NO1agViScD
Addressing the heterogeneous manifestations of psoriatic arthritis (PsA) can be challenging for physicians. But how is disease control defined in PsA? What are appropriate treatment targets for use in clinical practice? Join Dr. Alexis Ogdie and Dr. Philip Mease for an overview of composite measures used to assess disease activity and ongoing discussions surrounding disease control and treatment targets for patients with PsA.